Merck ditches biosimilar Lantus, but will that ease the path for Mylan’s rival insulin product?

Jumping into the multibillion-dollar market for biosimilar insulin products seemed like a no-brainer for Merck & Co., which is one of the world’s leaders in diabetes. But the company’s Lantus biosim partnership with Korea’s Samsung Bioepis has faced